Filing Flows › ANI Pharmaceuticals (ANIP) › Operating margin
ANI Pharmaceuticals (ANIP) operating margin by quarter
ANI Pharmaceuticals' operating margin was 18.0% in Q3 2026 (third quarter 2026), +2.8 pts from Q2 2026. Over the last 7 quarters it ranged from 6.6% (Q2 2025) to 18.0% (Q3 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 18.0% | +2.8 pts | +2.1 pts |
| Q2 2026 | 15.2% | -1.2 pts | +8.6 pts |
| Q1 2026 | 16.4% | +2.3 pts | +3.1 pts |
| Q4 2025 | 14.1% | -1.8 pts | — |
| Q3 2025 | 15.9% | +9.3 pts | — |
| Q2 2025 | 6.6% | -6.7 pts | — |
| Q1 2025 | 13.3% | — | — |
Q3 2026 at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ANI Pharmaceuticals' operating margin?
ANI Pharmaceuticals' operating margin was 18.0% in Q3 2026 (third quarter 2026), +2.8 pts from Q2 2026.
How has ANI Pharmaceuticals' operating margin changed?
Over the last 7 quarters it ranged from 6.6% (Q2 2025) to 18.0% (Q3 2026).